×
About 1,765 results

ALLMedicine™ Bullous Pemphigoid Center

Research & Reviews  642 results

Drug-Aggravated Bullous Pemphigoid in a 47-year-old Asian Woman - A Case Report.
https://doi.org/10.2174/1574886317666220518091554
Current Drug Safety; N D, H H et. al.

May 21st, 2022 - Bullous pemphigoid is the most common chronic recurrent autoimmune subepidermal blistering disorder most prevalent in geriatric population. It varies widely in clinical presentation ranging from tense bullae to intense generalized pruritus. It is ...

Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids a...
https://doi.org/10.1007/s40257-022-00688-x 10.1111/bjd.20881
American Journal of Clinical Dermatology; Tsai YJ, Cho YT et. al.

May 18th, 2022 - Rituximab is a potential initial adjuvant therapy for bullous pemphigoid, yet clinical experience is scarce. We aimed to examine the clinical outcomes and safety of initial combination therapy with systemic corticosteroids and adjuvant rituximab f...

Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primaril...
https://doi.org/10.1111/1346-8138.16428
The Journal of Dermatology; Takamura S, Teraki Y

May 12th, 2022 - We report a patient with bullous pemphigoid (BP) who was successfully treated with dupilumab monotherapy. To clarify the underlying mechanism of this effective treatment, we investigated the dynamics of a variety of cytokine-producing T cells befo...

Journal club: Bullous pemphigoid.
https://doi.org/10.1684/ejd.2022.4211
European Journal of Dermatology : EJD; Rosell-Diaz A, Lefevre MA et. al.

May 7th, 2022 - Journal club: Bullous pemphigoid.|2022|Rosell-Diaz A,Lefevre MA,Mohme S,Alband N,Nogueira M,|

Infantile bullous pemphigoid.
https://doi.org/10.1684/ejd.2022.4229
European Journal of Dermatology : EJD; Cozzani E, Herzum A et. al.

May 7th, 2022 - Infantile bullous pemphigoid.|2022|Cozzani E,Herzum A,Gasparini G,Viglizzo G,Parodi A,|drug therapy,

see more →

Drugs  2 results see all →

Clinicaltrials.gov  12 results

Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells
https://clinicaltrials.gov/ct2/show/NCT04805021

Jan 11th, 2022 - Acquired hemophilia A is a rare condition of hemostasis secondary to the development of antibodies against factor VIII. This is a potentially serious pathology that can be life-threatening due to the major risk of bleeding caused by the sometimes ...

The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors
https://clinicaltrials.gov/ct2/show/NCT04469582

Sep 23rd, 2020 - Bullous pemphigoid (BP) is the most common chronic autoimmune skin disease which is characterized by the presentation of subepidermical blisters and mostly affects elderly patients . Recent studies have suggested that dipeptidyl peptidase-4 inhibi...

Ixekizumab in the Treatment of Bullous Pemphigoid
https://clinicaltrials.gov/ct2/show/NCT03099538

May 21st, 2020 - BP is the most common auto-immune blistering disease of the skin and causes significant morbidity. BP disproportionally affects the elderly population and the current, non-specific immunosuppressive therapies, in addition to patient comorbidities,...

Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients
https://clinicaltrials.gov/ct2/show/NCT03320798

Oct 25th, 2017 - The aim was to determine whether neurologic disorders, especially dementia, influences outcome and mortality of patients with bullous pemphigoid.

Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid
https://clinicaltrials.gov/ct2/show/NCT02360202

Aug 30th, 2017 - The main objective of the study is to evaluate whether there is fluid retention after introduction of clobetasol propionate treatment from 10 g/day dosage to 40 g / day in patients with bullous pemphigoid. Bio-impedance is a noninvasive device for...

see more →

News  45 results

Age, Skin Cancer Risks for ICI-Induced Bullous Pemphigoid
https://www.medscape.com/viewarticle/972516

Apr 21st, 2022 - Bullous pemphigoid, an immune-mediated condition chacterized by large, fluid-filled blisters on the skin, is a rare but serious complication of cancer therapy with immune checkpoint inhibitors (ICIs) that may result in treatment interruption or ce...

Blistering Lesions in a Newborn
https://www.mdedge.com/dermatology/article/253884/pediatrics/blistering-lesions-newborn
Gabriella Alvarez, BS, Shivani Shah, DO, MPH et. al.

Apr 19th, 2022 - The Diagnosis: Epidermolysis Bullosa Our patient was found to have epidermolysis bullosa (EB), a rare genetic disease in which the superficial layers of the skin separate to form vesicles or bullae due to a mutation in the keratin 14 gene, KRT14.

Diffuse Urticarial Rash in a Pregnant Patient
https://www.mdedge.com/dermatology/article/251345/urticaria/diffuse-urticarial-rash-pregnant-patient
Abraham M. Korman, MD, Jessica A. Kaffenberger, MD

Feb 2nd, 2022 - The Diagnosis: Pemphigoid Gestationis A lesional biopsy showed a subepidermal split with eosinophils and neutrophils. Perilesional biopsy for direct immunofluorescence (DIF) showed linear deposition of 3+ C3 along the basement membrane zone.

Blisters in a Comatose Elderly Woman
https://www.mdedge.com/dermatology/article/250850/dermatopathology/blisters-comatose-elderly-woman
David J. Kurtyka, MD, Karl M. Saardi, MD et. al.

Jan 19th, 2022 - The Diagnosis: Coma Blisters Histologic examination revealed pauci-inflammatory subepidermal blisters with swelling of eccrine cells, signaling impending gland necrosis (Figure). Direct immunofluorescence testing on perilesional skin was negative.

A Starter Guide to Immunofluorescence Testing in Dermatology
https://www.mdedge.com/dermatology/article/249292/dermatopathology/starter-guide-immunofluorescence-testing-dermatology
Margaret Maria Cocks, MD, PhD

Dec 1st, 2021 - Direct immunofluorescence (DIF) is the go-to diagnostic test when evaluating vesiculobullous eruptions, connective tissue disease, and vasculitis. This specialized test allows visualization of autoantibodies and their reaction products in the epid.

see more →

Patient Education  5 results see all →